JLE

Epileptic Disorders

MENU

Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases Volume 23, issue 2, April 2021

Video

  • Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases

Tables

Authors
Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
* Correspondence: Ali Mir Consultant Pediatric Neurologist & Epileptologist, Department of Pediatric Neurology, Neuroscience Center King Fahad Specialist Hospital, Ammar Bin Thabit Street, Dammam – 31444, Saudi Arabia

Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus, associated with multiple etiologies. Etiology-specific treatments, such as hemispherotomy for Rasmussen encephalitis, lesionectomy for focal cortical dysplasia, and metabolic correction for non-ketotic hyperglycemia, have proven to be efficacious in treating EPC, but, in general, EPC is difficult to treat and often drug-resistant, and there is little evidence to guide therapy. We report the successful treatment of EPC with perampanel in two pediatric patients. The first patient was a 12-year-old boy with neuronal ceroid lipofuscinosis (NCL) who started to have EPC around the age of 10 years, characterized by left hemifacial myoclonic twitches and hemi-body jerks that were almost continuous throughout the day and disappeared during sleep. He had failed several antiepileptic drugs (AEDs). The EPC stopped within three days of initiating perampanel. The second patient was a six-year-old boy with POLG-related mitochondrial disease who presented to the emergency room with continuous jerky movements of the right arm and face after a trivial head injury. After failing several AEDs, including a midazolam drip, the EPC was controlled with perampanel. Both patients showed dramatic improvement and continue to show sustained efficacy after around five months of follow-up. Based on our observations, perampanel, which has a unique mechanism of action, appears to be a promising therapeutic option for treating EPC. [Published with video sequence].